Reposted by @manjuggm.bsky.social
The final study presented at #ASCO26 Plenary: RASolute-302 results show daraxonrasib meeting all primary and key secondary endpoints, demonstrating significant and clinically meaningful improvements in OS, PFS, and ORR in metastatic #PDAC: bit.ly/49r62n1
#ASCODailyNews